^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SHR-A1912
i
Other names: SHR-A1912
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
CD79b-targeted antibody-drug conjugate
Related drugs:
2ms
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor (clinicaltrials.gov)
P1, N=924, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1 trial • Metastases
|
capecitabine • oxaliplatin • SHR-A1904 • SHR-A1912
5ms
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma (clinicaltrials.gov)
P1/2, N=132, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
SHR-A1912
6ms
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas (clinicaltrials.gov)
P1, N=170, Enrolling by invitation, Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2023 --> Mar 2024
Enrollment status • Trial primary completion date
|
SHR-A1912
7ms
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma (clinicaltrials.gov)
P1/2, N=132, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1/2 trial
|
SHR-A1912
11ms
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas (clinicaltrials.gov)
P1, N=170, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | N=123 --> 170 | Trial completion date: Jun 2024 --> Mar 2025
Enrollment change • Trial completion date
|
SHR-A1912
Share via
